These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Long-chain polyphosphates impair SARS-CoV-2 infection and replication. Ferrucci V; Kong DY; Asadzadeh F; Marrone L; Boccia A; Siciliano R; Criscuolo G; Anastasio C; Quarantelli F; Comegna M; Pisano I; Passariello M; Iacobucci I; Monica RD; Izzo B; Cerino P; Fusco G; Viscardi M; Brandi S; Pierri BM; Borriello G; Tiberio C; Atripaldi L; Bianchi M; Paolella G; Capoluongo E; Castaldo G; Chiariotti L; Monti M; De Lorenzo C; Yun KS; Pascarella S; Cheong JH; Kim HY; Zollo M Sci Signal; 2021 Jul; 14(690):. PubMed ID: 34230209 [TBL] [Abstract][Full Text] [Related]
23. Inhibition of S-protein RBD and hACE2 Interaction for Control of SARSCoV- 2 Infection (COVID-19). Nayak SK Mini Rev Med Chem; 2021; 21(6):689-703. PubMed ID: 33208074 [TBL] [Abstract][Full Text] [Related]
24. COVID19 Drug Repository: text-mining the literature in search of putative COVID19 therapeutics. Tworowski D; Gorohovski A; Mukherjee S; Carmi G; Levy E; Detroja R; Mukherjee SB; Frenkel-Morgenstern M Nucleic Acids Res; 2021 Jan; 49(D1):D1113-D1121. PubMed ID: 33166390 [TBL] [Abstract][Full Text] [Related]
25. Repositioning of histamine H Ge S; Wang X; Hou Y; Lv Y; Wang C; He H Eur J Pharmacol; 2021 Apr; 896():173897. PubMed ID: 33497607 [TBL] [Abstract][Full Text] [Related]
26. H Yang G Am J Physiol Cell Physiol; 2020 Aug; 319(2):C244-C249. PubMed ID: 32515982 [TBL] [Abstract][Full Text] [Related]
27. Comparison of Binding Site of Remdesivir and Its Metabolites with NSP12-NSP7-NSP8, and NSP3 of SARS CoV-2 Virus and Alternative Potential Drugs for COVID-19 Treatment. Jung LS; Gund TM; Narayan M Protein J; 2020 Dec; 39(6):619-630. PubMed ID: 33185784 [TBL] [Abstract][Full Text] [Related]
29. SARS-CoV-2 entry inhibitors by dual targeting TMPRSS2 and ACE2: An in silico drug repurposing study. Baby K; Maity S; Mehta CH; Suresh A; Nayak UY; Nayak Y Eur J Pharmacol; 2021 Apr; 896():173922. PubMed ID: 33539819 [TBL] [Abstract][Full Text] [Related]
30. Insights into SARS-CoV-2: Medicinal Chemistry Approaches to Combat Its Structural and Functional Biology. Zhuo LS; Wang MS; Yang JF; Xu HC; Huang W; Shang LQ; Yang GF Top Curr Chem (Cham); 2021 Apr; 379(3):23. PubMed ID: 33886017 [TBL] [Abstract][Full Text] [Related]
31. Overview of antiviral drug candidates targeting coronaviral 3C-like main proteases. Chen CC; Yu X; Kuo CJ; Min J; Chen S; Ma L; Liu K; Guo RT FEBS J; 2021 Sep; 288(17):5089-5121. PubMed ID: 33400393 [TBL] [Abstract][Full Text] [Related]
32. A transferable deep learning approach to fast screen potential antiviral drugs against SARS-CoV-2. Wang S; Sun Q; Xu Y; Pei J; Lai L Brief Bioinform; 2021 Nov; 22(6):. PubMed ID: 34081143 [TBL] [Abstract][Full Text] [Related]
33. The TMPRSS2 Inhibitor Nafamostat Reduces SARS-CoV-2 Pulmonary Infection in Mouse Models of COVID-19. Li K; Meyerholz DK; Bartlett JA; McCray PB mBio; 2021 Aug; 12(4):e0097021. PubMed ID: 34340553 [TBL] [Abstract][Full Text] [Related]
34. Black tea bioactives as inhibitors of multiple targets of SARS-CoV-2 (3CLpro, PLpro and RdRp): a virtual screening and molecular dynamic simulation study. Gogoi M; Borkotoky M; Borchetia S; Chowdhury P; Mahanta S; Barooah AK J Biomol Struct Dyn; 2022 Sep; 40(15):7143-7166. PubMed ID: 33715595 [TBL] [Abstract][Full Text] [Related]
38. Strong Binding of Leupeptin with TMPRSS2 Protease May Be an Alternative to Camostat and Nafamostat for SARS-CoV-2 Repurposed Drug: Evaluation from Molecular Docking and Molecular Dynamics Simulations. Ramakrishnan J; Kandasamy S; Iruthayaraj A; Magudeeswaran S; Chinnasamy K; Poomani K Appl Biochem Biotechnol; 2021 Jun; 193(6):1909-1923. PubMed ID: 33512650 [TBL] [Abstract][Full Text] [Related]
39. Designing therapeutic strategies to combat severe acute respiratory syndrome coronavirus-2 disease: COVID-19. Rohilla S Drug Dev Res; 2021 Feb; 82(1):12-26. PubMed ID: 33216381 [TBL] [Abstract][Full Text] [Related]
40. Understanding Individual SARS-CoV-2 Proteins for Targeted Drug Development against COVID-19. van de Leemput J; Han Z Mol Cell Biol; 2021 Aug; 41(9):e0018521. PubMed ID: 34124934 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]